Three scientific Prizes awarded by DebioPharm
© 2013 EPFL
Debiopharm Group™ and the EPFL presented the ‘Debiopharm Group Life Sciences Award 2013’ and the ‘Junior Debiopharm Group Life Sciences Awards 2013’ during the annual EPFL SV- Life Science Symposium, the "LSS2013".
Debiopharm Group™ (Debiopharm), the Swiss-based global biopharmaceutical company that focuses on the development of prescription drugs targeting unmet medical needs as well as companion diagnostics, presents today the ‘Debiopharm Group™ Life Sciences Award 2013’ to Professor Grégoire Courtine for his outstanding research on ‘Restoring Motor Functions after Spinal Cord Injury’.
Above photo (left to right): Prof. Jeff Hubbell, Dean of the EPFL Faculty of Life Sciences, Dr Max Murone, Associate Director, Early Projects Research & Evaluation, Debiopharm International SA, Prof. Grégoire Courtine, awardee and IRP chair in spinal cord repair, Dr Andres McAllister, CSO, Debiopharm International SA, Dr Pascale Boyer-Barresi, Senior Business Analyst & Communication, Debiopharm International SA
* * *
The two ‘Junior Debiopharm Group™ Life Sciences Awards 2013’ were attributed to Dr Leanne Li for her research on cancer and the nervous system and to Dr Stéphane Baudouin for his work on the heterogeneity of psychiatric disorders.
Above photo (left to right) : Prof. Jeff Hubbell, Dean of the EPFL Faculty of Life Sciences, Dr Max Murone, Associate Director, Early Projects Research & Evaluation, Debiopharm International SA, Dr Stephane Baudouin and Dr Leanne Li, junior awardees, Dr Andres McAllister, CSO, Debiopharm International SA, Dr Pascale Boyer-Barresi, Senior Business Analyst & Communication, Debiopharm International SA
Organized by the Brain Mind Institute (BMI), homed at the EPFL School of Life Sciences, the ceremony took place at the EPFL-Lausanne campus. The theme of this year's symposium is ’Motor Control - from neural circuits and diseases to neuroprosthetics.’
About Debiopharm Group™
Debiopharm Group™ (Debiopharm) is a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs. The group in-licenses, develops and/or co-develops promising biological and small molecule drug candidates having reached clinical development phases I, II or III, as well as earlier stage candidates.
“We were impressed by the quality of research that our nominees have provided and are happy to present them with the Awards,” said Rolland-Yves Mauvernay, President and founder of Debiopharm Group™. “We wish them successful careers and are confident that their work will be applied to the development of life saving treatments.”